Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Total Liabilities: 2023-2024

Historic Total Liabilities for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $68.6 million.

  • Silence Therapeutics' Total Liabilities rose 157.40% to $72.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.7 million, marking a year-over-year increase of 159.22%. This contributed to the annual value of $68.6 million for FY2024, which is 29.60% down from last year.
  • Latest data reveals that Silence Therapeutics reported Total Liabilities of $68.6 million as of FY2024, which was down 29.60% from $97.5 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Total Liabilities registered a high of $97.5 million during FY2023, and its lowest value of -$27.2 million during FY2022.
  • For the 3-year period, Silence Therapeutics' Total Liabilities averaged around $46.3 million, with its median value being $68.6 million (2024).
  • As far as peak fluctuations go, Silence Therapeutics' Total Liabilities plummeted by 132.05% in 2022, and later soared by 458.01% in 2023.
  • Over the past 5 years, Silence Therapeutics' Total Liabilities (MRY) stood at -$11.6 million in 2020, then fell by 0.84% to -$11.7 million in 2021, then tumbled by 132.05% to -$27.2 million in 2022, then surged by 458.01% to $97.5 million in 2023, then fell by 29.60% to $68.6 million in 2024.
  • Its Total Liabilities was $68.6 million in FY2024, compared to $97.5 million in FY2023 and -$27.2 million in FY2022.